Oncolytics completes U.K. phase I trial enrolment Oncolytics completes U.K. phase I trial enrolment
Oncolytics Biotech Inc (C:ONC)
Shares Issued 76,606,085
Last Close 8/15/2012 $3.05
Thursday August 16 2012 - News Release
Dr. Matt Coffey reports
ONCOLYTICS BIOTECH INC. COMPLETES PATIENT ENROLLMENT IN THE U.K. PHASE I CLINICAL TRIAL INVESTIGATING REOLYSIN IN COMBINATION WITH CYCLOPHOSPHAMIDE IN PATIENTS WITH ADVANCED MALIGNANCIES
Oncolytics Biotech Inc. has completed patient enrolment in its United Kingdom phase I clinical trial using intravenously administered Reolysin in combination with cyclophosphamide in patients with advanced malignancies (REO 012).
"We are pleased to complete enrollment of this technical study examining cyclophosphamide's potential to modulate the immune system's response to REOLYSIN," said Dr. Matt Coffey, COO of Oncolytics. "Studies of this type help to advance our understanding of the interaction between the immune system and our product."
The primary objective of the open label, dose-escalating, non-randomized, 36-patient study is to determine the Minimum Effective Immunomodulatory Dose (MED) of cyclophosphamide necessary to obtain successful immune modulation. Secondary objectives of the trial include assessing the safety profile of the combination and gathering any evidence of antitumor activity.
Eligible patients include those who have been diagnosed with advanced or metastatic solid tumors, including pancreatic, lung and ovarian cancers that are refractory to standard therapy, or for which no standard curative therapy exists.
The principal investigators for the study are Dr. James Spicer of King's College, London, Dr. Johann de Bono and Dr. Kevin Harrington of the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.
We seek Safe Harbor.
© 2012 Canjex Publishing Ltd.